About 85% of a cohort of Alaskans who received the hepatitis B vaccine at age 6 months or older showed evidence of protection after 35 years, although some may require a booster dose, according to a study presented at the 2017 Liver Meeting.

“No chronic hepatitis B infections were identified in the cohort,” according to lead study author Michael Bruce, MD, MPH, an epidemiology team leader in the CDC’s Arctic Investigation Program Division of Preparedness and Emerging Infections, in Anchorage.

The study was the longest hepatitis B vaccine follow-up to date, noted Belgian vaccine expert Pierre Van Damme, MD, PhD, who was not involved with the research.

Read more…https://www.idse.net/Hepatitis/Article/06-18/How-Durable-Is-the-Hepatitis-B-Vaccine-/48739